The Advanced Therapeutics Industrial Acceleration Partnership (ATIAP) is a proposed four-year, $75-million national partnership between CASTL, Stem Cell Network, Capital BioVentures and OBIO®. It is designed to connect promising Canadian discoveries with the clinical, manufacturing, commercialization and workforce support needed to advance and scale in Canada.
This Economic Primer outlines the proposed model, investment and outcomes, including how ATIAP could support Canadian development activity, attract private capital and build industry-ready talent.
Explore the Economic Primer to learn more about ATIAP and the economic opportunity it is designed to address.
